C-path to lead new task force aimed at accelerating drug development for mitochondrial and inherited metabolic diseases
TUCSON, Ariz., January 11, 2024 — Critical Path Institute (C-Path) today announced the launch of a task force focused on accelerating drug development for mitochondrial and inherited metabolic diseases. The task force will lay the groundwork for specific solutions, offering valuable insights that aim to contribute to regulatory decision-making.
C-Path’s demonstrated expertise will be leveraged to ensure success, specifically its track record in generating tangible solutions that have accelerated drug development in rare and pediatric ...









